Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label single-arm study of AEB071 in CD79-mutant diffuse large B-cell lymphoma
NL-OMON38217Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotrastaurin in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL), sponsored by Novartis. Primary endpoints: Occurrence of dose-limiting toxicities and Occurrence of adverse events and serious adverse events. Started Nov 2011; status: active, not recruiting.
02
Drugs
sotrastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON38217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38217.